GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK) posted its earnings results on Wednesday. The company reported GBX 172 earnings per share (EPS) for the quarter, reports. GSK had a return on equity of 18.08% and a net margin of 8.02%.

GSK Stock Up 4.6%

LON GSK opened at GBX 2,035.49 on Wednesday. The stock has a market capitalization of £82.11 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,066. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a fifty day moving average of GBX 1,829.26 and a 200-day moving average of GBX 1,655.56.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Berenberg Bank raised their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a report on Wednesday, January 7th. Citigroup reaffirmed a “buy” rating and set a GBX 1,900 price objective on shares of GSK in a research note on Tuesday, January 27th. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Thursday, January 8th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of GBX 1,839.29.

Insider Activity at GSK

In related news, insider Jonathan Symonds purchased 1,650 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were bought at an average price of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker acquired 441 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were purchased at an average price of GBX 1,809 per share, with a total value of £7,977.69. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.